Nonstatin lipid-lowering medications
| Medication | Mechanism of action | LDL-C reduction | Trials |
|---|---|---|---|
| Ezetimibe | Reduces absorption of cholesterol from small intestine | 15%–25% | IMPROVE IT27 |
| Bempedoic acid | Inhibition of adenosine triphosphate citrate lyase | 15%–20% (alone) 25%–30% (with ezetimibe) | CLEAR Outcomes study (pending) |
| PCSK9 inhibitors | Inhibition of PCSK9 protein resulting in more LDL receptors available, and increased uptake of LDL-C into cells | 45%–60% | FOURIER, 201530 ODYSSEY Outcomes 201519 |
LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9